Lacosamide G.L. (Lacosamide)

Lacosamide enhances the slow inactivation of voltage‑gated sodium channels, stabilizing neuronal membranes and reducing hyper‑excitability. It may also bind to the collapsin response mediator protein‑2 (CRMP‑2), further modulating neuronal activity.

The dosing regimen is individualized by the prescribing clinician based on the patient’s clinical status, seizure type, and prior therapy. Lacosamide G.L. is supplied as an intravenous solution for controlled administration under medical supervision.

Safety data for lacosamide in pregnancy are limited and the pregnancy category is unknown. It should be used only if the potential benefit justifies the potential risk to the fetus. Breastfeeding decisions should be made in consultation with a healthcare professional.

Submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and required import documentation.

Compared with traditional sodium‑channel blockers such as carbamazepine, lacosamide selectively enhances slow inactivation, which may result in a different side‑effect profile and lower risk of certain drug‑drug interactions. Clinical choice depends on individual patient factors and therapeutic goals.

The product should be stored at 2‑8 °C, kept refrigerated, protected from light, and should not be frozen or shaken. If temporary storage at controlled room temperature is unavoidable, limit exposure to less than 24 hours.

Lacosamide G.L. is given as an intravenous infusion by a qualified healthcare professional. The solution is typically diluted in compatible IV fluids and infused over a prescribed period, with monitoring for efficacy and tolerability throughout the administration.

Serious adverse events include cardiac arrhythmias such as atrioventricular block, severe skin reactions like Stevens‑Johnson syndrome, and respiratory depression. Patients with pre‑existing cardiac conduction abnormalities or respiratory compromise should be closely monitored.

Patients with known hypersensitivity to lacosamide or any component of the formulation, those with significant cardiac conduction abnormalities, and individuals for whom intravenous therapy is contraindicated should avoid using this product.